However, the α7 nAChR agonists have the disadvantages of insufficient selectivity, tendency to desensitize receptors, and lack of data related to clinical trials; these factors limit the application of α7 nAChR agonists in the treatment of depression [24, 174]. The gene discussed is CHRNA7; the disease is depressive symptom measurement.